var data={"title":"Pertussis infection in infants and children: Treatment and prevention","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pertussis infection in infants and children: Treatment and prevention</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/contributors\" class=\"contributor contributor_credentials\">Sylvia Yeh, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/contributors\" class=\"contributor contributor_credentials\">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/contributors\" class=\"contributor contributor_credentials\">Mary M Torchia, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 09, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The treatment and prevention of pertussis (whooping cough) infection in infants and children will be discussed here. The clinical presentation, including complications, and the diagnosis of pertussis in infants and children; the microbiology, epidemiology, and pathogenesis of pertussis infection; and the clinical features, treatment, and prevention of pertussis in adolescents and adults are discussed separately:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=pertussis-infection-in-infants-and-children-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Pertussis infection in infants and children: Clinical features and diagnosis&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=pertussis-infection-epidemiology-microbiology-and-pathogenesis\" class=\"medical medical_review\">&quot;Pertussis infection: Epidemiology, microbiology, and pathogenesis&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=pertussis-infection-in-adolescents-and-adults-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Pertussis infection in adolescents and adults: Clinical manifestations and diagnosis&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=pertussis-infection-in-adolescents-and-adults-treatment-and-prevention\" class=\"medical medical_review\">&quot;Pertussis infection in adolescents and adults: Treatment and prevention&quot;</a>.)</p><p/><p>The treatment and prevention recommendations in this topic review are generally consistent with those of the United States Centers for Disease Control and Prevention [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/1\" class=\"abstract_t\">1</a>] and the American Academy of Pediatrics [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H94180645\"><span class=\"h1\">CLINICAL COURSE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pertussis infection often results in a protracted illness. Frequent coughing paroxysms interfere with daily function. Young infants can develop serious complications, including failure to thrive, apnea, pneumonia, respiratory failure, seizures, and death. Without antimicrobial therapy, the child is contagious throughout much of the protracted illness. (See <a href=\"topic.htm?path=pertussis-infection-in-infants-and-children-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Pertussis infection in infants and children: Clinical features and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H90991858\"><span class=\"h1\">MANAGEMENT</span></p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h2\">Supportive care</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Supportive care is the mainstay of management for <em>Bordetella pertussis</em> infection.</p><p class=\"headingAnchor\" id=\"H939470696\"><span class=\"h3\">Hospitalization</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Indications</strong> &ndash; Indications for hospitalization in infants and children with pertussis infection or suspected pertussis infection include [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/3-5\" class=\"abstract_t\">3-5</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Respiratory distress, including tachypnea, retractions, nasal flaring, grunting, and the use of accessory muscles</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Evidence of pneumonia (see <a href=\"topic.htm?path=community-acquired-pneumonia-in-children-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Community-acquired pneumonia in children: Clinical features and diagnosis&quot;</a>)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Inability to feed</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Cyanosis or apnea, with or without coughing</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Seizures</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Age &lt;4 months (see <a href=\"#H90992297\" class=\"local\">'Special population: Infants &lt;4 months'</a> below)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Isolation</strong> &ndash; Standard precautions, as well as droplet precautions (mask within 3 feet), are recommended for children with pertussis who are admitted to the hospital [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/2\" class=\"abstract_t\">2</a>]. These precautions should be in effect until five days of effective therapy have been administered or three weeks after the onset of symptoms in untreated patients. (See <a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection#H356549551\" class=\"medical medical_review\">&quot;Infection prevention: Precautions for preventing transmission of infection&quot;, section on 'Droplet precautions'</a>.)</p><p/><p class=\"bulletIndent1\">Contact precautions are not necessary for <em>B. pertussis</em> but may be indicated for other conditions in the differential diagnosis until a diagnosis is confirmed (eg, respiratory syncytial virus, adenovirus, parainfluenza virus). (See <a href=\"topic.htm?path=pertussis-infection-in-infants-and-children-clinical-features-and-diagnosis#H24\" class=\"medical medical_review\">&quot;Pertussis infection in infants and children: Clinical features and diagnosis&quot;, section on 'Differential diagnosis'</a> and <a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection#H954996324\" class=\"medical medical_review\">&quot;Infection prevention: Precautions for preventing transmission of infection&quot;, section on 'Contact precautions'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Discharge criteria</strong> &ndash; <strong>Minimum</strong> criteria for discharge include:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Ability to tolerate coughing episodes without becoming hypoxic <span class=\"nowrap\">and/or</span> bradycardic; most infants who are admitted to the hospital with pertussis continue to have coughing paroxysms after discharge</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Ability to eat enough to gain weight</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Reliable caretakers who are comfortable caring for the child at home</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Assurance of close outpatient follow-up</p><p/><p class=\"headingAnchor\" id=\"H4\"><span class=\"h3\">Fluids and nutrition</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Infants and children with frequent paroxysms of cough may have increased fluid and energy needs, which can be difficult to meet if the infant is coughing or vomiting. The child's fluid and nutritional status should be monitored closely, whether the child is admitted to the hospital or cared for at home.</p><p>Intravenous hydration and nasogastric feeding may be required for some patients. The nasogastric tube may stimulate the cough reflex in some infants; however, nasogastric feedings should be attempted before parenteral nutrition for infants who are unable to gain weight because of severe coughing paroxysms.</p><p class=\"headingAnchor\" id=\"H939470078\"><span class=\"h3\">Management of cough</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The paroxysmal cough of pertussis may be severe and protracted; it is the main cause of morbidity from pertussis. Known triggers for coughing paroxysms (eg, exercise, cold temperatures, nasopharyngeal [NP] suctioning) should be avoided if possible &ndash; although NP suctioning may be necessary for diagnosis. (See <a href=\"topic.htm?path=pertussis-infection-in-infants-and-children-clinical-features-and-diagnosis#H23\" class=\"medical medical_review\">&quot;Pertussis infection in infants and children: Clinical features and diagnosis&quot;, section on 'Laboratory confirmation'</a>.)</p><p>We do not suggest symptomatic therapies for pertussis-related cough. In small trials and a systematic review, symptomatic treatments, including bronchodilators, corticosteroids, antihistamines, and antitussive agents, have not been proven to be beneficial in patients with pertussis [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/6-10\" class=\"abstract_t\">6-10</a>]. In general, the risks of these therapies outweigh the benefits, particularly for opioid cough suppressants, which may adversely affect respiration. However, based on anecdotal experience, some clinicians may attempt a trial of inhaled beta-agonists for infants with compromised respiratory status. Although pertussis-associated cough did not improve in two small trials (total of 34 patients) [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/7,8\" class=\"abstract_t\">7,8</a>], increased risks of beta-agonists in patients with pertussis have not been reported.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Antimicrobial therapy</span></p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">Indications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>When administered early in the course (ie, within seven days of symptom onset), antimicrobial therapy for pertussis may shorten the duration of symptoms and decrease transmission to susceptible contacts [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/11,12\" class=\"abstract_t\">11,12</a>]. Treatment is particularly important for infants &lt;6 months because they are at increased risk for complications. In addition, if not treated, they remain culture positive for longer periods than do older children and adults [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/13-15\" class=\"abstract_t\">13-15</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend antimicrobial treatment for individuals who have <em>B. pertussis</em> isolated from pertussis cultures or positive polymerase chain reaction (PCR) within three weeks of cough onset (individuals &gt;1 year) or six weeks of cough onset (individuals &lt;1 year) [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/1,16\" class=\"abstract_t\">1,16</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We also recommend treatment for infants and children with a clinical diagnosis of pertussis (with or without laboratory confirmation) who have had symptoms &lt;21 days. (See <a href=\"topic.htm?path=pertussis-infection-in-infants-and-children-clinical-features-and-diagnosis#H936816785\" class=\"medical medical_review\">&quot;Pertussis infection in infants and children: Clinical features and diagnosis&quot;, section on 'Clinical diagnosis'</a>.)</p><p/><p class=\"bulletIndent1\">Antimicrobial therapy should be initiated based upon clinical suspicion and not on laboratory confirmation, because laboratory confirmation may take up to one week, depending on the laboratory facilities and testing methods that are available. (See <a href=\"topic.htm?path=pertussis-infection-in-infants-and-children-clinical-features-and-diagnosis#H23\" class=\"medical medical_review\">&quot;Pertussis infection in infants and children: Clinical features and diagnosis&quot;, section on 'Laboratory confirmation'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antimicrobial therapy also may be indicated for patients who have had &gt;21 days of symptoms, particularly those who are likely to be in contact with high-risk individuals [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/17,18\" class=\"abstract_t\">17,18</a>], although the utility of therapy in such patients is less clear than for patients with &lt;21 days of symptoms.</p><p/><p>Early treatment (ie, within seven days of symptom onset) may decrease the severity of symptoms [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/19\" class=\"abstract_t\">19</a>]. However, most patients do not come to medical attention until the paroxysmal phase, which occurs one to two weeks after illness onset. Clinical trials and observational studies of treatment during the paroxysmal stage have yielded inconsistent results regarding the ability of treatment to alter the clinical course [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/20-23\" class=\"abstract_t\">20-23</a>]. A systematic review of randomized and quasi-randomized trials of antibiotics for the treatment of pertussis concluded that antibiotic treatment does not alter the clinical course [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/12\" class=\"abstract_t\">12</a>]. However, in many of the studies that were included, treatment was initiated after the paroxysmal phase.</p><p>Patients are most contagious during the catarrhal stage and through the first three weeks after onset of coughing spells [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/2\" class=\"abstract_t\">2</a>]. A systematic review of randomized and quasi-randomized trials of antibiotics concluded that antibiotic treatment is effective in eradicating pertussis from the nasopharynx, thereby reducing the risk of transmission [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/12\" class=\"abstract_t\">12</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h3\">Choice of regimen</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The macrolide antibiotics, <a href=\"topic.htm?path=erythromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">erythromycin</a>, <a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a>, and <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a> are the preferred antimicrobial therapies for the treatment of pertussis [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/1,2,24\" class=\"abstract_t\">1,2,24</a>]. Erythromycin-resistant <em>B. pertussis</em> rarely has been reported. The preferred regimen varies with age (<a href=\"image.htm?imageKey=PEDS%2F75339\" class=\"graphic graphic_table graphicRef75339 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/1,21\" class=\"abstract_t\">1,21</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Infants younger than one month</strong> &ndash; <a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Azithromycin</a> is the recommended macrolide antibiotic for the treatment of pertussis in infants younger than one month of age. It is preferred over <a href=\"topic.htm?path=erythromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">erythromycin</a>; <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a> is not recommended.</p><p/><p class=\"bulletIndent1\">Both <a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> and <a href=\"topic.htm?path=erythromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">erythromycin</a> are associated with increased risk of infantile hypertrophic pyloric stenosis (IHPS), particularly in infants younger than two weeks [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/25-30\" class=\"abstract_t\">25-30</a>]. The risk of IHPS with <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a> is not known [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/31\" class=\"abstract_t\">31</a>]. IHPS should be considered in young infants who develop vomiting within one month of therapy with a macrolide antibiotic given in the first month of life. Cases of pyloric stenosis associated with oral macrolide antibiotics should be reported to the <a href=\"http://www.fda.gov/Safety/MedWatch/default.htm&amp;token=SHauxSdf9qNc6lLK16E8IPbyjEFMv8mTkYk65soc8qsZMFRMv9J+X3VuesSuXUid3aLA+xJr6vDaLvZteEOMGQ==&amp;TOPIC_ID=5997\" target=\"_blank\" class=\"external\">US Food and Drug Administration (FDA) Safety Information and Adverse Event Reporting Program</a>. (See <a href=\"topic.htm?path=infantile-hypertrophic-pyloric-stenosis#H4\" class=\"medical medical_review\">&quot;Infantile hypertrophic pyloric stenosis&quot;, section on 'Clinical manifestations'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Infants and children older than one month</strong> &ndash; Any of the macrolide antibiotics (<a href=\"image.htm?imageKey=PEDS%2F75339\" class=\"graphic graphic_table graphicRef75339 \">table 1</a>) can be used for the treatment of pertussis in infants and children older than one month of age. Neither <a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> nor <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a> is licensed by the FDA for use in infants younger than six months; however, azithromycin is commonly employed for pertussis treatment and prophylaxis in young infants.</p><p/><p><a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Azithromycin</a> and <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a> have a more convenient dosing schedule than <a href=\"topic.htm?path=erythromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">erythromycin</a> and are better tolerated [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/32,33\" class=\"abstract_t\">32,33</a>]. Azithromycin and clarithromycin have excellent in vitro activity and have been evaluated in several clinical trials [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/33-36\" class=\"abstract_t\">33-36</a>]. In the largest trial, 477 children with confirmed or suspected pertussis were randomly assigned to treatment with erythromycin or azithromycin [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/33\" class=\"abstract_t\">33</a>]. Pertussis was eradicated from the nasopharynx of children who had positive cultures (24 percent of the total), regardless of which antibiotic they received. However, 90 percent of children who took azithromycin completed therapy, compared with 55 percent who took erythromycin.</p><p><a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Trimethoprim-sulfamethoxazole</a> (TMP-SMX) is an alternative for children older than two months who have a contraindication to or cannot tolerate macrolide agents [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/2\" class=\"abstract_t\">2</a>]. TMP-SMX should not be used in infants younger than two months of age because of the potential risk of kernicterus related to bilirubin displacement.</p><p>Beta-lactam antibiotics (<a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a>, <a href=\"topic.htm?path=amoxicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin</a>, cephalosporins) have variable activity against <em>B. pertussis</em> and are not recommended. Ampicillin and amoxicillin do not eradicate <em>B. pertussis</em> from the nasopharynx [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/37\" class=\"abstract_t\">37</a>]. Neither <a href=\"topic.htm?path=doxycycline-pediatric-drug-information\" class=\"drug drug_pediatric\">doxycycline</a> nor fluoroquinolone antibiotics are recommended for use in young children because of potential adverse effects. (See <a href=\"topic.htm?path=tetracyclines#H14\" class=\"medical medical_review\">&quot;Tetracyclines&quot;, section on 'Adverse reactions'</a> and <a href=\"topic.htm?path=fluoroquinolones#H23\" class=\"medical medical_review\">&quot;Fluoroquinolones&quot;, section on 'Use in children'</a>.)</p><p>The duration of therapy varies depends upon the agent (<a href=\"image.htm?imageKey=PEDS%2F75339\" class=\"graphic graphic_table graphicRef75339 \">table 1</a>). A meta-analysis evaluated randomized and quasi-randomized controlled trials of antibiotics for the treatment of pertussis that compared short-term (<a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> for three days, <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a> for seven days, or <a href=\"topic.htm?path=erythromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">erythromycin</a> estolate for seven days) and long-term macrolide therapy (erythromycin estolate or erythromycin for 14 days) for the eradication of <em>B. pertussis</em> from the nasopharynx [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/12\" class=\"abstract_t\">12</a>]. The report concluded that short-term therapy was as effective and associated with significantly fewer side effects. However, we continue to suggest a 14-day course of erythromycin, because relapses have been reported after courses of 7 to 10 days [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/38\" class=\"abstract_t\">38</a>]. We also continue to suggest a five-day course of azithromycin, because the number of subjects treated with the shorter duration of azithromycin in the meta-analysis was small (&lt;20 subjects) [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/12\" class=\"abstract_t\">12</a>].</p><p class=\"headingAnchor\" id=\"H90992297\"><span class=\"h2\">Special population: Infants &lt;4 months</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Infants younger than four months are at increased risk for severe or fatal pertussis infection. In a review of 53 fatal cases of pertussis in infants younger than four months from a single state (1998 to 2014), the case fatality rate was 1.2 percent [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/39\" class=\"abstract_t\">39</a>].</p><p>The recommendations in this section are consistent with guidance provided by the <a href=\"https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Immunization/pertussis.aspx&amp;token=YXVx7qSYWdpODmpLx16x6TItHyB6PTBIrfD/bq2dOOHltnFKVrXpMBIHzWDSQBZ0tiRvxxTfCBmxcNv2nUhYGIkNF6TRozwCrJaEl/05/uk=&amp;TOPIC_ID=5997\" target=\"_blank\" class=\"external\">California Department of Public Health</a> (DPH) during the 2010 California pertussis outbreak [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/5\" class=\"abstract_t\">5</a>].</p><p class=\"headingAnchor\" id=\"H90992982\"><span class=\"h3\">Treatment setting</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Infants younger than four months with pertussis should be evaluated with a low threshold to admit to the hospital. Infants younger than four months are at increased risk of severe or fatal pertussis [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/40,41\" class=\"abstract_t\">40,41</a>].</p><p>Hospitalization at a medical center with a pediatric intensive care unit is suggested for infants younger than four months of age and white blood cell (WBC) count &gt;30,000 <span class=\"nowrap\">cell/microL</span> (which is associated with significant morbidity [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/39,42,43\" class=\"abstract_t\">39,42,43</a>]) [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/5\" class=\"abstract_t\">5</a>]. The severity of illness in young infants is unpredictable; clinical decline may occur rapidly and without warning [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/44\" class=\"abstract_t\">44</a>]. Intensive care may be required for the management of apnea, seizures, respiratory failure, pulmonary hypertension, <span class=\"nowrap\">and/or</span> cardiac failure. If the admitting hospital cannot provide intensive care, transfer to a hospital with an intensive care unit may be warranted [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"#H90992676\" class=\"local\">'Critically ill infants'</a> below.)</p><p class=\"headingAnchor\" id=\"H90992989\"><span class=\"h3\">Antimicrobial therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antimicrobial therapy for pertussis in infants &lt;4 months of age should be initiated immediately upon suspicion of pertussis (<a href=\"image.htm?imageKey=PEDS%2F75339\" class=\"graphic graphic_table graphicRef75339 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/5\" class=\"abstract_t\">5</a>]. Laboratory confirmation should not delay the initiation of treatment. (See <a href=\"topic.htm?path=pertussis-infection-in-infants-and-children-clinical-features-and-diagnosis#H957516886\" class=\"medical medical_review\">&quot;Pertussis infection in infants and children: Clinical features and diagnosis&quot;, section on 'Infants &lt;4 months'</a> and <a href=\"#H6\" class=\"local\">'Antimicrobial therapy'</a> above.)</p><p class=\"headingAnchor\" id=\"H90992996\"><span class=\"h3\">Monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The respiratory rate, heart rate, oxygen saturation, and WBC count of infants who are admitted to the hospital for pertussis (suspected or confirmed) should be monitored. The California DPH guidelines suggest monitoring WBC counts that are increasing every six hours and monitoring WBC counts that are stable or decreasing once per day [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/5\" class=\"abstract_t\">5</a>].</p><p>Case series suggest that exchange transfusion or leukapheresis may be helpful in the management of pertussis-related respiratory failure, pulmonary hypertension, and cardiac failure [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/45-50\" class=\"abstract_t\">45-50</a>], but it must be performed <strong>before</strong> the infant is in severe distress or has multiorgan failure [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/39,49\" class=\"abstract_t\">39,49</a>]. (See <a href=\"#H90992676\" class=\"local\">'Critically ill infants'</a> below.)</p><p>Documentation of oral intake and the severity of coughing spells (eg, whether they are associated with hypoxia or bradycardia) and apneic episodes are helpful in discharge planning. The frequency of coughing spells and apnea decrease before severity; thus, discharge decisions should be based upon the severity of coughing spells and apnea rather than the frequency [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"#H939470696\" class=\"local\">'Hospitalization'</a> above.)</p><p class=\"headingAnchor\" id=\"H90992676\"><span class=\"h3\">Critically ill infants</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Critically ill infants include those with apnea, seizures, or pneumonia complicated by respiratory failure, pulmonary hypertension, <span class=\"nowrap\">and/or</span> cardiac failure. Complicated pneumonia usually occurs in association with WBC count &ge;30,000 <span class=\"nowrap\">cells/microL</span> [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/39\" class=\"abstract_t\">39</a>].</p><p>A full discussion of the intensive care management of infants with pertussis is beyond the scope of this review. Guidelines for the intensive care unit management of infants with pertussis are provided by the <a href=\"https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Immunization/pertussis.aspx&amp;token=YXVx7qSYWdpODmpLx16x6TItHyB6PTBIrfD/bq2dOOHltnFKVrXpMBIHzWDSQBZ0tiRvxxTfCBmxcNv2nUhYGIkNF6TRozwCrJaEl/05/uk=&amp;TOPIC_ID=5997\" target=\"_blank\" class=\"external\">California DPH</a>, and summarized below. Management or consultation with an intensivist may be most appropriate in these instances.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Apnea &ndash; Infants with significant apnea (eg, if adequate ventilation is a concern) may require mechanical ventilation.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Seizures &ndash; Seizures in infants with pertussis are treated in the same manner as seizures due to other causes. (See <a href=\"topic.htm?path=seizures-and-epilepsy-in-children-initial-treatment-and-monitoring\" class=\"medical medical_review\">&quot;Seizures and epilepsy in children: Initial treatment and monitoring&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pneumonia complicated by refractory hypoxemia, pulmonary hypertension, <span class=\"nowrap\">and/or</span> cardiac failure &ndash; This scenario is typically associated with extreme leukocytosis and has a mortality of up to 80 percent [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/39,41,50,51\" class=\"abstract_t\">39,41,50,51</a>]. In young infants with pertussis, WBC count &ge;30,000 <span class=\"nowrap\">cells/microL</span> has been associated with increased severity and death.</p><p/><p class=\"bulletIndent1\">Double-volume exchange transfusion may be warranted for infants with WBC count &ge;30,000 <span class=\"nowrap\">cells/microL</span> and pneumonia with heart rate &ge;180 <span class=\"nowrap\">beats/minute</span> [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/5,49\" class=\"abstract_t\">5,49</a>]. In case series, hypoxemia, pulmonary hypertension, and cardiac failure that were unresponsive to other measures improved after exchange transfusion [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/45-49\" class=\"abstract_t\">45-49</a>]. In a 2014 literature review of 47 reported cases of critical pertussis treated with exchange transfusion, 30 (64 percent) survived [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/52\" class=\"abstract_t\">52</a>]. The technique for double volume exchange transfusion is the same as that used for newborns with hyperbilirubinemia [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/5,53\" class=\"abstract_t\">5,53</a>]. (See <a href=\"topic.htm?path=treatment-of-unconjugated-hyperbilirubinemia-in-term-and-late-preterm-infants#H19\" class=\"medical medical_review\">&quot;Treatment of unconjugated hyperbilirubinemia in term and late preterm infants&quot;, section on 'Exchange transfusion'</a>.)</p><p/><p class=\"bulletIndent1\">For infants who do not improve with exchange transfusion, extracorporeal membrane oxygenation (ECMO) may be warranted as a life-saving measure; however, in a review of 61 children with pertussis who were treated with ECMO, the mortality rate was 70.5 percent [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/50\" class=\"abstract_t\">50</a>].</p><p/><p class=\"bulletIndent1\">Given the sparsity of data, consultation with an experienced pediatric intensivist is suggested before undertaking exchange transfusion or ECMO for the treatment of pertussis in young infants.</p><p/><p class=\"headingAnchor\" id=\"H90991851\"><span class=\"h1\">PREVENTION</span></p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Postexposure prophylaxis</span></p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h3\">Indications and timing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest postexposure antimicrobial prophylaxis for all household and close contacts of the index case and for exposed individuals at high risk for severe or complicated pertussis, even if the exposed person is fully immunized. Postexposure prophylaxis is most effective when initiated within 21 days of the onset of cough in the index patient [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/1\" class=\"abstract_t\">1</a>]. The utility of postexposure prophylaxis after 21 days of onset of cough in the index case is unclear.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Close contacts</strong> &ndash; Close contacts are defined by [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/1,2\" class=\"abstract_t\">1,2</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Living in the same household</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Face-to-face exposure within 3 feet of a symptomatic patient</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Direct contact with respiratory, oral, or nasal secretions from a symptomatic patient</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Sharing the same confined space in close proximity with a symptomatic patient for &ge;1 hour</p><p/><p class=\"bulletIndent1\">Local public health officials should be consulted for recommendations regarding control of pertussis in schools. Prophylaxis for entire schools or classrooms usually is not recommended.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>High risk</strong> &ndash; Individuals who should receive postexposure prophylaxis because they are at high risk for severe or complicated pertussis or they may expose individuals who are at high risk include [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/1\" class=\"abstract_t\">1</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Infants younger than one year, particularly those younger than four months</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Pregnant women</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Persons with immunodeficiency</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Persons with underlying medical conditions (chronic lung disease, respiratory insufficiency, cystic fibrosis)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Persons who have contact with infants</p><p/><p>Factors to consider in decisions about postexposure prophylaxis include the contagiousness of the patient, the intensity of the exposure, the potential for consequences of severe pertussis in the contact, and the possibility for secondary exposure of persons at high risk of severe infection from the contact [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/1\" class=\"abstract_t\">1</a>]. The benefits of prophylaxis must be weighed against the potential adverse effects. (See <a href=\"#H9\" class=\"local\">'Choice of regimen'</a> above.)</p><p>Retrospective epidemiologic studies suggest that early chemoprophylaxis is associated with decreased risk of transmission of pertussis [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/54-56\" class=\"abstract_t\">54-56</a>]. In the only randomized trial, <a href=\"topic.htm?path=erythromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">erythromycin</a> was 68 percent efficacious in preventing culture-confirmed pertussis in household contacts [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/57\" class=\"abstract_t\">57</a>]. However, there was no difference in duration of respiratory symptoms between the treatment and placebo groups. Twenty percent of household contacts in both groups had symptoms consistent with pertussis before treatment was initiated. A post-hoc analysis excluding these subjects demonstrated no difference in the secondary attack rate between treatment and placebo groups, but the sample size may have been too small to detect a significant difference. Therefore, antimicrobial prophylaxis continues to be recommended for close contacts of patients with pertussis.</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h3\">Regimen</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The antibiotic regimens for postexposure prophylaxis are identical to those used for treatment of pertussis (<a href=\"image.htm?imageKey=PEDS%2F75339\" class=\"graphic graphic_table graphicRef75339 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/1,2,54,55\" class=\"abstract_t\">1,2,54,55</a>].</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h2\">Immunization</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We recommend age-appropriate immunization against pertussis for infants, children, adolescents, and adults (<a href=\"image.htm?imageKey=PEDS%2F82617%7EPEDS%2F58209%7EID%2F82634\" class=\"graphic graphic_figure graphicRef82617 graphicRef58209 graphicRef82634 \">figure 1A-C</a>). Immunization against pertussis has dramatically reduced the <a href=\"https://www.cdc.gov/pertussis/images/incidence-graph.png&amp;token=Ca72vix96YlXok2PJXI08/Wy2b7Xgm4bmu+dERhSRlS8mS++DIQLE5tTTteBf1GuosKSS5+qVxBoXhGhwfHPww==&amp;TOPIC_ID=5997\" target=\"_blank\" class=\"external\">burden of disease</a>.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Routine immunization</strong> &ndash; Routine immunization of infants, children, adolescents, and adults (particularly pregnant women) is the most important preventive strategy [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/1\" class=\"abstract_t\">1</a>]. Routine vaccination against pertussis is discussed separately. (See <a href=\"topic.htm?path=diphtheria-tetanus-and-pertussis-immunization-in-infants-and-children-0-through-6-years-of-age\" class=\"medical medical_review\">&quot;Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age&quot;</a> and <a href=\"topic.htm?path=diphtheria-tetanus-and-pertussis-immunization-in-children-7-through-18-years-of-age\" class=\"medical medical_review\">&quot;Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age&quot;</a> and <a href=\"topic.htm?path=pertussis-infection-in-adolescents-and-adults-treatment-and-prevention#H12882667\" class=\"medical medical_review\">&quot;Pertussis infection in adolescents and adults: Treatment and prevention&quot;, section on 'Vaccination'</a> and <a href=\"topic.htm?path=immunizations-during-pregnancy#H17\" class=\"medical medical_review\">&quot;Immunizations during pregnancy&quot;, section on 'Tetanus, diphtheria, and pertussis vaccination'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Immunization of contacts</strong> &ndash; Close contacts of the index case who are younger than seven years of age and who are unimmunized or underimmunized should have pertussis immunization initiated or continued according to the recommended schedule [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/2\" class=\"abstract_t\">2</a>]. (See <a href=\"topic.htm?path=diphtheria-tetanus-and-pertussis-immunization-in-infants-and-children-0-through-6-years-of-age#H11\" class=\"medical medical_review\">&quot;Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age&quot;, section on 'Vaccine schedule'</a> and <a href=\"topic.htm?path=diphtheria-tetanus-and-pertussis-immunization-in-children-7-through-18-years-of-age#H12\" class=\"medical medical_review\">&quot;Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age&quot;, section on 'Vaccine schedule'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Immunization after pertussis infection</strong> &ndash; Well-documented pertussis infection (eg, a positive culture for <em>B. pertussis</em> or an epidemiologic link to a culture-positive case) is likely to confer immunity against pertussis [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/58\" class=\"abstract_t\">58</a>]. However, the duration of immunity is unknown, and pertussis infection can reoccur as immunity wanes. We agree with the American Academy of Pediatrics recommendation that children who have had well-documented pertussis disease complete the primary diphtheria-tetanus-pertussis vaccine series with diphtheria-tetanus-acellular pertussis vaccine (DTaP) [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/2\" class=\"abstract_t\">2</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Neonatal immunization</strong> &ndash; Early neonatal immunization is a strategy that is being studied [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/59-61\" class=\"abstract_t\">59-61</a>] but is not yet recommended.</p><p/><p class=\"headingAnchor\" id=\"H90991111\"><span class=\"h2\">Infection control</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Infection control measures for hospitalized patients are discussed above. (See <a href=\"#H939470696\" class=\"local\">'Hospitalization'</a> above.)</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h2\">Return to school or day care</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Because of the high risk of transmission, infected children should be excluded from school or day care until they have completed five days of effective antimicrobial therapy, or, if they are not treated, 21 days after the onset of symptoms [<a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/2\" class=\"abstract_t\">2</a>]. Contacts of an infected child should be closely observed for development of respiratory symptoms for at least 21 days after the last contact with the infected individual.</p><p class=\"headingAnchor\" id=\"H3722692503\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-pertussis\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Pertussis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword[s] of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topic (see <a href=\"topic.htm?path=whooping-cough-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Whooping cough (The Basics)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=vaccines-for-infants-and-children-age-0-to-6-years-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)&quot;</a> and <a href=\"topic.htm?path=vaccines-for-children-age-7-to-18-years-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Vaccines for children age 7 to 18 years (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H26\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Supportive care is the mainstay of treatment for pertussis in infants and children. Particular attention must be paid to the child's fluid and nutritional status. Indications for hospitalization include increased work of breathing, pneumonia, inability to feed, cyanosis, apnea, seizures, and age &lt;4 months (given concerns for rapid deterioration). For infants &lt;4 months, hospitalization at a major medical center with a pediatric intensive care unit may be desirable because clinical decline may occur rapidly and without warning. (See <a href=\"#H2\" class=\"local\">'Supportive care'</a> above and <a href=\"#H90992297\" class=\"local\">'Special population: Infants &lt;4 months'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Known triggers for coughing paroxysms (eg, exercise, cold temperatures, nasopharyngeal suctioning) should be avoided if possible. Symptomatic treatments including bronchodilators, corticosteroids, antihistamines, and antitussive agents have not been proven to be beneficial in improving the cough in patients with pertussis. (See <a href=\"#H939470078\" class=\"local\">'Management of cough'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>When administered early in the course, antimicrobial therapy can shorten the duration of symptoms and decrease transmission to close contacts. Early initiation of antimicrobial therapy entails a high degree of clinical suspicion, since laboratory confirmation of the diagnosis can take as long as a week. (See <a href=\"topic.htm?path=pertussis-infection-in-infants-and-children-clinical-features-and-diagnosis#H21\" class=\"medical medical_review\">&quot;Pertussis infection in infants and children: Clinical features and diagnosis&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Given the ability of antibiotics to eradicate pertussis from the nasopharynx, we recommend antimicrobial treatment for infants and children who have <em>Bordetella pertussis</em> isolated from cultures or have positive polymerase chain reaction for pertussis (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). (See <a href=\"#H8\" class=\"local\">'Indications'</a> above and <a href=\"topic.htm?path=pertussis-infection-in-infants-and-children-clinical-features-and-diagnosis#H21\" class=\"medical medical_review\">&quot;Pertussis infection in infants and children: Clinical features and diagnosis&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We also recommend antimicrobial treatment for patients with a clinical diagnosis of pertussis who have had symptoms for less than 21 days (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). (See <a href=\"#H8\" class=\"local\">'Indications'</a> above and <a href=\"topic.htm?path=pertussis-infection-in-infants-and-children-clinical-features-and-diagnosis#H21\" class=\"medical medical_review\">&quot;Pertussis infection in infants and children: Clinical features and diagnosis&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend macrolide antibiotics for the treatment and prophylaxis of pertussis (<a href=\"image.htm?imageKey=PEDS%2F75339\" class=\"graphic graphic_table graphicRef75339 \">table 1</a>) (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Trimethoprim-sulfamethoxazole</a> may be an alternative for patients who have a contraindication to or cannot tolerate macrolide agents (<a href=\"image.htm?imageKey=PEDS%2F75339\" class=\"graphic graphic_table graphicRef75339 \">table 1</a>). (See <a href=\"#H9\" class=\"local\">'Choice of regimen'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Infantile hypertrophic pyloric stenosis should be considered in young infants who develop vomiting within one month of therapy with a macrolide antibiotic given in the first month of life. (See <a href=\"#H9\" class=\"local\">'Choice of regimen'</a> above and <a href=\"topic.htm?path=infantile-hypertrophic-pyloric-stenosis\" class=\"medical medical_review\">&quot;Infantile hypertrophic pyloric stenosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest antimicrobial prophylaxis for household and close contacts of the index case and for individuals at high risk for severe or complicated pertussis (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). (See <a href=\"#H14\" class=\"local\">'Postexposure prophylaxis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The regimen for antimicrobial prophylaxis is the same as that for treatment (<a href=\"image.htm?imageKey=PEDS%2F75339\" class=\"graphic graphic_table graphicRef75339 \">table 1</a>). Antimicrobial prophylaxis should be initiated within 21 days of onset of cough in the index case. (See <a href=\"#H19\" class=\"local\">'Regimen'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In countries where the diphtheria-tetanus-acellular pertussis (DTaP) vaccine is available, we suggest that incompletely immunized children (&lt;7 years of age) with well-documented pertussis infection complete immunization with DTaP rather than with diphtheria-tetanus vaccine (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H23\" class=\"local\">'Immunization'</a> above and <a href=\"topic.htm?path=diphtheria-tetanus-and-pertussis-immunization-in-infants-and-children-0-through-6-years-of-age\" class=\"medical medical_review\">&quot;Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Children with pertussis or suspected pertussis may return to school or day care after they have completed five days of effective antimicrobial therapy or, if they are not treated, 21 days after the onset of symptoms. (See <a href=\"#H24\" class=\"local\">'Return to school or day care'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/1\" class=\"nounderline abstract_t\">Tiwari T, Murphy TV, Moran J, National Immunization Program, CDC. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Recomm Rep 2005; 54:1.</a></li><li class=\"breakAll\">American Academy of Pediatrics. Pertussis (whooping cough). In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.609.</li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/3\" class=\"nounderline abstract_t\">Halperin SA, Wang EE, Law B, et al. Epidemiological features of pertussis in hospitalized patients in Canada, 1991-1997: report of the Immunization Monitoring Program--Active (IMPACT). Clin Infect Dis 1999; 28:1238.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/4\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Pertussis--United States, 2001-2003. MMWR Morb Mortal Wkly Rep 2005; 54:1283.</a></li><li class=\"breakAll\">Cherry JD, Harrison R, Bradley JS, et al. Pertussis in young infants -- Guidance for clinicians. May 2010, updated June 2011. www.cdph.ca.gov/HealthInfo/discond/Pages/Pertussis.aspx (Accessed on July 10, 2015).</li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/6\" class=\"nounderline abstract_t\">Wang K, Bettiol S, Thompson MJ, et al. Symptomatic treatment of the cough in whooping cough. Cochrane Database Syst Rev 2014; :CD003257.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/7\" class=\"nounderline abstract_t\">Mertsola J, Viljanen MK, Ruuskanen O. Salbutamol in the treatment of whooping cough. Scand J Infect Dis 1986; 18:593.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/8\" class=\"nounderline abstract_t\">Krantz I, Norrby SR, Trollfors B. Salbutamol vs. placebo for treatment of pertussis. Pediatr Infect Dis 1985; 4:638.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/9\" class=\"nounderline abstract_t\">Roberts I, Gavin R, Lennon D. Randomized controlled trial of steroids in pertussis. Pediatr Infect Dis J 1992; 11:982.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/10\" class=\"nounderline abstract_t\">Zoumboulakis D, Anagnostakis D, Albanis V, Matsaniotis N. Steroids in treatment of pertussis. A controlled clinical trial. Arch Dis Child 1973; 48:51.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/11\" class=\"nounderline abstract_t\">Bortolussi R, Miller B, Ledwith M, Halperin S. Clinical course of pertussis in immunized children. Pediatr Infect Dis J 1995; 14:870.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/12\" class=\"nounderline abstract_t\">Altunaiji S, Kukuruzovic R, Curtis N, Massie J. Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev 2007; :CD004404.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/13\" class=\"nounderline abstract_t\">Kwantes W, Joynson DH, Williams WO. Bordetella pertussis isolation in general practice: 1977-79 whooping cough epidemic in West Glamorgan. J Hyg (Lond) 1983; 90:149.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/14\" class=\"nounderline abstract_t\">Henry R, Dorman D, Skinner J, Mellis C. Limitations of erythromycin in whooping cough. Med J Aust 1981; 2:108.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/15\" class=\"nounderline abstract_t\">Riitta H. The effect of early erythromycin treatment on the infectiousness of whooping cough patients. Acta Paediatr Scand 1982; 298:10.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/16\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Pertussis--United States, 1997-2000. MMWR Morb Mortal Wkly Rep 2002; 51:73.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention. Guidelines for the control of pertussis outbreaks. www.cdc.gov/pertussis/outbreaks/guide/index.html (Accessed on July 10, 2015).</li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/18\" class=\"nounderline abstract_t\">Hewlett EL, Edwards KM. Clinical practice. Pertussis--not just for kids. N Engl J Med 2005; 352:1215.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/19\" class=\"nounderline abstract_t\">Bass JW. Pertussis: current status of prevention and treatment. Pediatr Infect Dis 1985; 4:614.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/20\" class=\"nounderline abstract_t\">Hoppe JE. Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis. The Erythromycin Study Group. Pediatr Infect Dis J 1992; 11:189.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/21\" class=\"nounderline abstract_t\">Bass JW, Klenk EL, Kotheimer JB, et al. Antimicrobial treatment of pertussis. J Pediatr 1969; 75:768.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/22\" class=\"nounderline abstract_t\">Steketee RW, Wassilak SG, Adkins WN Jr, et al. Evidence for a high attack rate and efficacy of erythromycin prophylaxis in a pertussis outbreak in a facility for the developmentally disabled. J Infect Dis 1988; 157:434.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/23\" class=\"nounderline abstract_t\">Bergquist SO, Bernander S, Dahnsj&ouml; H, Sundel&ouml;f B. Erythromycin in the treatment of pertussis: a study of bacteriologic and clinical effects. Pediatr Infect Dis J 1987; 6:458.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/24\" class=\"nounderline abstract_t\">Tapiainen T, Aittoniemi J, Immonen J, et al. Finnish guidelines for the treatment of community-acquired pneumonia and pertussis in children. Acta Paediatr 2016; 105:39.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/25\" class=\"nounderline abstract_t\">Honein MA, Paulozzi LJ, Himelright IM, et al. Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromcyin: a case review and cohort study. Lancet 1999; 354:2101.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/26\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Hypertrophic pyloric stenosis in infants following pertussis prophylaxis with erythromycin--Knoxville, Tennessee, 1999. MMWR Morb Mortal Wkly Rep 1999; 48:1117.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/27\" class=\"nounderline abstract_t\">Eberly MD, Eide MB, Thompson JL, Nylund CM. Azithromycin in early infancy and pyloric stenosis. Pediatrics 2015; 135:483.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/28\" class=\"nounderline abstract_t\">Mahon BE, Rosenman MB, Kleiman MB. Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J Pediatr 2001; 139:380.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/29\" class=\"nounderline abstract_t\">Cooper WO, Griffin MR, Arbogast P, et al. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med 2002; 156:647.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/30\" class=\"nounderline abstract_t\">Lund M, Pasternak B, Davidsen RB, et al. Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study. BMJ 2014; 348:g1908.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/31\" class=\"nounderline abstract_t\">Hauben M, Amsden GW. The association of erythromycin and infantile hypertrophic pyloric stenosis: causal or coincidental? Drug Saf 2002; 25:929.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/32\" class=\"nounderline abstract_t\">Friedman DS, Curtis CR, Schauer SL, et al. Surveillance for transmission and antibiotic adverse events among neonates and adults exposed to a healthcare worker with pertussis. Infect Control Hosp Epidemiol 2004; 25:967.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/33\" class=\"nounderline abstract_t\">Langley JM, Halperin SA, Boucher FD, et al. Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. Pediatrics 2004; 114:e96.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/34\" class=\"nounderline abstract_t\">Lebel MH, Mehra S. Efficacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: a prospective, randomized, single blind trial. Pediatr Infect Dis J 2001; 20:1149.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/35\" class=\"nounderline abstract_t\">Aoyama T, Sunakawa K, Iwata S, et al. Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. J Pediatr 1996; 129:761.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/36\" class=\"nounderline abstract_t\">Ba&#263;e A, Zrni&#263; T, Begovac J, et al. Short-term treatment of pertussis with azithromycin in infants and young children. Eur J Clin Microbiol Infect Dis 1999; 18:296.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/37\" class=\"nounderline abstract_t\">Trollfors B. Effect of erythromycin and amoxycillin on Bordetella pertussis in the nasopharynx. Infection 1978; 6:228.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/38\" class=\"nounderline abstract_t\">Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory committee (ACIP). MMWR Recomm Rep 1991; 40:1.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/39\" class=\"nounderline abstract_t\">Winter K, Zipprich J, Harriman K, et al. Risk Factors Associated With Infant Deaths From Pertussis: A Case-Control Study. Clin Infect Dis 2015; 61:1099.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/40\" class=\"nounderline abstract_t\">Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005; 18:326.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/41\" class=\"nounderline abstract_t\">Paddock CD, Sanden GN, Cherry JD, et al. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis 2008; 47:328.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/42\" class=\"nounderline abstract_t\">Mikelova LK, Halperin SA, Scheifele D, et al. Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada. J Pediatr 2003; 143:576.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/43\" class=\"nounderline abstract_t\">Pierce C, Klein N, Peters M. Is leukocytosis a predictor of mortality in severe pertussis infection? Intensive Care Med 2000; 26:1512.</a></li><li class=\"breakAll\">American Academy of Pediatrics. Pertussis in young infants. www.aap-ca.org/clinical/pertussis/pertussis_in_young_infants.html (Accessed on February 14, 2012).</li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/45\" class=\"nounderline abstract_t\">Rowlands HE, Goldman AP, Harrington K, et al. Impact of rapid leukodepletion on the outcome of severe clinical pertussis in young infants. Pediatrics 2010; 126:e816.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/46\" class=\"nounderline abstract_t\">Romano MJ, Weber MD, Weisse ME, Siu BL. Pertussis pneumonia, hypoxemia, hyperleukocytosis, and pulmonary hypertension: improvement in oxygenation after a double volume exchange transfusion. Pediatrics 2004; 114:e264.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/47\" class=\"nounderline abstract_t\">Grzeszczak MJ, Churchwell KB, Edwards KM, Pietsch J. Leukopheresis therapy for severe infantile pertussis with myocardial and pulmonary failure. Pediatr Crit Care Med 2006; 7:580.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/48\" class=\"nounderline abstract_t\">Donoso AF, Cruces PI, Camacho JF, et al. Exchange transfusion to reverse severe pertussis-induced cardiogenic shock. Pediatr Infect Dis J 2006; 25:846.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/49\" class=\"nounderline abstract_t\">Nieves D, Bradley JS, Gargas J, et al. Exchange blood transfusion in the management of severe pertussis in young infants. Pediatr Infect Dis J 2013; 32:698.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/50\" class=\"nounderline abstract_t\">Halasa NB, Barr FE, Johnson JE, Edwards KM. Fatal pulmonary hypertension associated with pertussis in infants: does extracorporeal membrane oxygenation have a role? Pediatrics 2003; 112:1274.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/51\" class=\"nounderline abstract_t\">Murray EL, Nieves D, Bradley JS, et al. Characteristics of severe Bordetella pertussis infection among infants &lt;/= 90 days of age admitted to pediatric intensive care units &ndash; Southern California, September 2009 - June 2011. J Pediatric Infect Dis Soc 2013; 2:1.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/52\" class=\"nounderline abstract_t\">Kuperman A, Hoffmann Y, Glikman D, et al. Severe pertussis and hyperleukocytosis: is it time to change for exchange? Transfusion 2014; 54:1630.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/53\" class=\"nounderline abstract_t\">Chen HN, Lee ML, Tsao LY. Exchange transfusion using peripheral vessels is safe and effective in newborn infants. Pediatrics 2008; 122:e905.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/54\" class=\"nounderline abstract_t\">Dodhia H, Miller E. Review of the evidence for the use of erythromycin in the management of persons exposed to pertussis. Epidemiol Infect 1998; 120:143.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/55\" class=\"nounderline abstract_t\">De Serres G, Boulianne N, Duval B. Field effectiveness of erythromycin prophylaxis to prevent pertussis within families. Pediatr Infect Dis J 1995; 14:969.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/56\" class=\"nounderline abstract_t\">Yeh SH. Pertussis: persistent pathogen, imperfect vaccines. Expert Rev Vaccines 2003; 2:113.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/57\" class=\"nounderline abstract_t\">Halperin SA, Bortolussi R, Langley JM, et al. A randomized, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive bordetella pertussis infection. Pediatrics 1999; 104:e42.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/58\" class=\"nounderline abstract_t\">Platt L, Thun M, Harriman K, Winter K. A Population-Based Study of Recurrent Symptomatic Bordetella pertussis Infections in Children in California, 2010-2015. Clin Infect Dis 2017; 65:2099.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/59\" class=\"nounderline abstract_t\">Knuf M, Schmitt HJ, Wolter J, et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr 2008; 152:655.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/60\" class=\"nounderline abstract_t\">Belloni C, De Silvestri A, Tinelli C, et al. Immunogenicity of a three-component acellular pertussis vaccine administered at birth. Pediatrics 2003; 111:1042.</a></li><li><a href=\"https://www.uptodate.com/contents/pertussis-infection-in-infants-and-children-treatment-and-prevention/abstract/61\" class=\"nounderline abstract_t\">Halasa NB, O'Shea A, Shi JR, et al. Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. J Pediatr 2008; 153:327.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5997 Version 37.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H26\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H94180645\" id=\"outline-link-H94180645\">CLINICAL COURSE</a></li><li><a href=\"#H90991858\" id=\"outline-link-H90991858\">MANAGEMENT</a><ul><li><a href=\"#H2\" id=\"outline-link-H2\">Supportive care</a><ul><li><a href=\"#H939470696\" id=\"outline-link-H939470696\">- Hospitalization</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">- Fluids and nutrition</a></li><li><a href=\"#H939470078\" id=\"outline-link-H939470078\">- Management of cough</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">Antimicrobial therapy</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">- Indications</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">- Choice of regimen</a></li></ul></li><li><a href=\"#H90992297\" id=\"outline-link-H90992297\">Special population: Infants &lt;4 months</a><ul><li><a href=\"#H90992982\" id=\"outline-link-H90992982\">- Treatment setting</a></li><li><a href=\"#H90992989\" id=\"outline-link-H90992989\">- Antimicrobial therapy</a></li><li><a href=\"#H90992996\" id=\"outline-link-H90992996\">- Monitoring</a></li><li><a href=\"#H90992676\" id=\"outline-link-H90992676\">- Critically ill infants</a></li></ul></li></ul></li><li><a href=\"#H90991851\" id=\"outline-link-H90991851\">PREVENTION</a><ul><li><a href=\"#H14\" id=\"outline-link-H14\">Postexposure prophylaxis</a><ul><li><a href=\"#H16\" id=\"outline-link-H16\">- Indications and timing</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">- Regimen</a></li></ul></li><li><a href=\"#H23\" id=\"outline-link-H23\">Immunization</a></li><li><a href=\"#H90991111\" id=\"outline-link-H90991111\">Infection control</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">Return to school or day care</a></li></ul></li><li><a href=\"#H3722692503\" id=\"outline-link-H3722692503\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H25\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H26\" id=\"outline-link-H26\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PEDS/5997|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/82617\" class=\"graphic graphic_figure\">- Childhood immunization schedule 0 through 6 years</a></li><li><a href=\"image.htm?imageKey=PEDS/58209\" class=\"graphic graphic_figure\">- Childhood immunization schedule 7 through 18 years</a></li><li><a href=\"image.htm?imageKey=ID/82634\" class=\"graphic graphic_figure\">- Vaccine schedule for healthy adults</a></li></ul></li><li><div id=\"PEDS/5997|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/75339\" class=\"graphic graphic_table\">- Pertussis Rx and prophylaxis</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=community-acquired-pneumonia-in-children-clinical-features-and-diagnosis\" class=\"medical medical_review\">Community-acquired pneumonia in children: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diphtheria-tetanus-and-pertussis-immunization-in-children-7-through-18-years-of-age\" class=\"medical medical_review\">Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diphtheria-tetanus-and-pertussis-immunization-in-infants-and-children-0-through-6-years-of-age\" class=\"medical medical_review\">Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fluoroquinolones\" class=\"medical medical_review\">Fluoroquinolones</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=immunizations-during-pregnancy\" class=\"medical medical_review\">Immunizations during pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infantile-hypertrophic-pyloric-stenosis\" class=\"medical medical_review\">Infantile hypertrophic pyloric stenosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection\" class=\"medical medical_review\">Infection prevention: Precautions for preventing transmission of infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vaccines-for-children-age-7-to-18-years-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Vaccines for children age 7 to 18 years (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vaccines-for-infants-and-children-age-0-to-6-years-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=whooping-cough-the-basics\" class=\"medical medical_basics\">Patient education: Whooping cough (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pertussis-infection-in-adolescents-and-adults-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Pertussis infection in adolescents and adults: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pertussis-infection-in-adolescents-and-adults-treatment-and-prevention\" class=\"medical medical_review\">Pertussis infection in adolescents and adults: Treatment and prevention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pertussis-infection-in-infants-and-children-clinical-features-and-diagnosis\" class=\"medical medical_review\">Pertussis infection in infants and children: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pertussis-infection-epidemiology-microbiology-and-pathogenesis\" class=\"medical medical_review\">Pertussis infection: Epidemiology, microbiology, and pathogenesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=seizures-and-epilepsy-in-children-initial-treatment-and-monitoring\" class=\"medical medical_review\">Seizures and epilepsy in children: Initial treatment and monitoring</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-pertussis\" class=\"medical medical_society_guidelines\">Society guideline links: Pertussis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tetracyclines\" class=\"medical medical_review\">Tetracyclines</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-unconjugated-hyperbilirubinemia-in-term-and-late-preterm-infants\" class=\"medical medical_review\">Treatment of unconjugated hyperbilirubinemia in term and late preterm infants</a></li></ul></div></div>","javascript":null}